A Harvard Business School Healthcare Alumni Association Q&A with Dr. Henry A. McKinnell, former Chairman and CEO of Pfizer.

The OUTREACH Study – Demonstrating that CAR-T therapies can be effectively administered in community cancer settings: In the ...

Willis Chandler is the new president and CEO of Knipper Health. The news came alongside the announcement that Frazier ...

Corina Dutcus, SVP, oncology global clinical development lead, Eisai, highlights how consistent survival data from the LEAP-002 study reaffirms lenvatinib’s value in first-line treatment of ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy therapies, announced a $105 million (€90 million) global license and transfer ...

Approval of Kerendia was based on results from the Phase III FINEARTS-HF trial, which demonstrated statistically significant ...

The majority of respondents not already enrolled in the program have concerns that the program won’t survive until the point ...

The specific parameters defined in your label, including patient population, line of therapy, and outcomes measured, will now ...

The new drug application is supported by 48-week data from the Phase III MK-8591A-051 and MK-8591A-052 trials, which showed ...

Bravecto Quantum is the first FDA-approved drug that treats and prevents flea and tick infestations on dogs for a duration of ...

rs6190 helps men build muscle mass and reduce diabetes risk, but increases cholesterol levels and elevates the risk of ...

A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models ...